1. Home
  2. IFRX vs GAIA Comparison

IFRX vs GAIA Comparison

Compare IFRX & GAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IFRX
  • GAIA
  • Stock Information
  • Founded
  • IFRX 2007
  • GAIA 1988
  • Country
  • IFRX Germany
  • GAIA United States
  • Employees
  • IFRX N/A
  • GAIA N/A
  • Industry
  • IFRX Biotechnology: Pharmaceutical Preparations
  • GAIA Movies/Entertainment
  • Sector
  • IFRX Health Care
  • GAIA Consumer Discretionary
  • Exchange
  • IFRX Nasdaq
  • GAIA Nasdaq
  • Market Cap
  • IFRX 143.7M
  • GAIA 143.5M
  • IPO Year
  • IFRX 2017
  • GAIA 1999
  • Fundamental
  • Price
  • IFRX $2.24
  • GAIA $4.82
  • Analyst Decision
  • IFRX Strong Buy
  • GAIA Strong Buy
  • Analyst Count
  • IFRX 1
  • GAIA 1
  • Target Price
  • IFRX $8.00
  • GAIA $7.00
  • AVG Volume (30 Days)
  • IFRX 401.6K
  • GAIA 26.9K
  • Earning Date
  • IFRX 11-08-2024
  • GAIA 11-04-2024
  • Dividend Yield
  • IFRX N/A
  • GAIA N/A
  • EPS Growth
  • IFRX N/A
  • GAIA N/A
  • EPS
  • IFRX N/A
  • GAIA N/A
  • Revenue
  • IFRX $187,930.00
  • GAIA $86,644,000.00
  • Revenue This Year
  • IFRX $435.15
  • GAIA $13.81
  • Revenue Next Year
  • IFRX $180.44
  • GAIA $14.30
  • P/E Ratio
  • IFRX N/A
  • GAIA N/A
  • Revenue Growth
  • IFRX 177.12
  • GAIA 9.28
  • 52 Week Low
  • IFRX $1.17
  • GAIA $2.56
  • 52 Week High
  • IFRX $2.82
  • GAIA $6.53
  • Technical
  • Relative Strength Index (RSI)
  • IFRX 52.76
  • GAIA 35.94
  • Support Level
  • IFRX $1.93
  • GAIA $4.38
  • Resistance Level
  • IFRX $2.74
  • GAIA $6.15
  • Average True Range (ATR)
  • IFRX 0.25
  • GAIA 0.31
  • MACD
  • IFRX -0.06
  • GAIA -0.14
  • Stochastic Oscillator
  • IFRX 34.88
  • GAIA 24.86

About IFRX InflaRx N.V.

InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its lead product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.

About GAIA Gaia Inc.

Gaia Inc is a video streaming service and community that provides curated conscious media in primary channels; Seeking Truth provides new and enlightening perspectives for today's changing world; Transformation provides a wealth of content in the niche areas of spiritual growth, personal development, and expanded consciousness; Alternative Healing channel features content focused on food and nutrition, holistic healing, alternative and integrative medicines, and longevity, and Yoga. Geographically, it derives a majority of its revenue from the United States and also has an international presence.

Share on Social Networks: